TME Pharma Increases Allocated Resources for Liquidity Contract

TME Pharma N.V., a Berlin-based clinical-stage biotechnology company, announced the increase in resources allocated to its liquidity contract with Invest Securities. This decision follows the closure of an account as part of an internal optimization process, contributing 349 treasury shares.

This move aligns with article 4 of the AMF Decision no. 2021-01, aiming to bolster the cash balance and securities resources of the liquidity account.

As of August 12, 2024, post-market close, the liquidity contract now includes 76,562 shares and a cash balance of €7,255.53. This is a significant increase from the half-year report of June 30, 2024, which noted 63,403 shares and a cash balance of €8,943.42.